Cost-Effectiveness of Cardiac Resynchronization Therapy in Patients with Symptomatic Heart Failure

Abstract

The incremental cost per QALY for cardiac resynchronization is similar to that of other commonly used interventions but is sensitive to changes in several key variables. Resynchronization therapy should not be considered in patients with comorbid illness that shortens life expectancy.